Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Stockholders held by MEDICINOVA, INC. on June 7, 2018. The filing details the voting results for director elections, auditor ratification, and an amendment to the company's equity incentive plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
As of the record date (April 12, 2018), the company had 41,129,073 shares issued and outstanding. A quorum was established with 26,919,207 shares present. The following matters were approved:
- Director Election: Yuichi Iwaki was elected as a Class II Director to serve until the 2021 Annual Meeting.
- For: 24,089,320
- Withheld: 911,014
- Broker Non-Vote: 1,918,873
- Auditor Ratification: BDO USA, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- For: 26,335,057
- Against: 291,083
- Abstain: 293,067
- Equity Plan Amendment: An amendment to the 2013 Equity Incentive Plan to increase the number of issuable shares by 1,500,000 was approved.
- For: 23,300,255
- Against: 1,248,552
- Abstain: 451,527
- Broker Non-Vote: 1,918,873
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the impact of the 1,500,000 share increase on the 2013 Equity Incentive Plan on future dilution.
- Confirm the tenure of the newly elected director, Yuichi Iwaki, through the 2021 Annual Meeting.
- Review the definitive proxy statement filed on April 26, 2018, for detailed background on the proposals.